Sobis behandling mot B-cellslymfom godkänd i EU

EU-kommissionen har lämnat ett villkorligt godkännande för Zynlonta som behandling av svårbehandlade former av diffust stort B-cellslymfom (DLBCL).

Jacob Lund blir global presschef för Astra Zeneca

Astrazeneca flyttar upp Jacob Lund till rollen som global presschef. Han är idag bolagets kommunikationsdirektör i Norden.

“We are Europe’s hotspot in life science”

The Medicon Valley Alliance has worked for competence development in life science in Denmark and Sweden for a quarter of a century. Anette Steenberg, CEO, sees the anniversary as a recognition of MVA’s explosive power.

He is zooming in on topical preparations

According to Zelmic CEO David Sagna, topical products in drug development is a growing market, and to keep pace with the development, the company is awaiting approval for its new GMP facility.

Swedish breakthrough in Alzheimer’s: “We can finally present great data”

Treatments for Alzheimer’s disease are currently among the hottest topics in drug development. Two Swedish research companies with high ambitions and successes in the field participated in Bioscience 2022 conference at Life City in Hagastaden, Stockholm.

Sobi-läkemedel nödgodkänt i USA för covid-behandling

Sobis läkemedel Kineret (anakinra) har nödgodkänts av den amerikanska läkemedelsmyndigheten FDA för behandling av covid-19-orsakad lunginflammation.

Stort vetenskapsmöte igång i Life City

Edward Kim blir ny CMO hos Orexo

Läkemedelsbolaget Orexo har utsett Edward Kim till ny Chief Medical Officer. Han ersätter Michael Sumner som går vidare till bolagets amerikanska dotterbolag i New Jersey.

She is Sweden´s new Minister of Healthcare

Today, Tuesday, Swedish Prime Minister Ulf Kristersson, who leads the Moderate Party and the centre-right coalition in Sweden, presented the government's new ministers. Christian Democrat Jakob Forssmed gets the role of Minister for Social Affairs and Acko Ankarberg Johansson (also of the Christian Democrat Party) becomes Minister for Health Care.

“We need to build flexible operating theatres”

Flexible operating theatres, micro-sensors on surgeons to monitor their well-being and 3D images projected onto organs to be operated on. These are a few ideas that three specialist surgeons are suggesting for the operating theatre of the future.

Cytel Inc acquires the SDS Group

The multinational statistical software developer and contract research organization Cytel Inc, headquartered in Massachusetts, USA, acquires the Swedish consulting company SDS Life Science.

The TFS family is growing

TFS HealthScience is a European based CRO company with broad expertise and experiences in the biotech and pharmaceutical sector. The company is growing and the TFS family welcomes new members.

Biosimilars bring price pressure, but are they sufficiently used?

When biosimilars were introduced just over 16 years ago, hopes were raised that they would give many more patients access to effective but otherwise extremely expensive treatments with biological drugs. So, how well has Swedish healthcare used biosimilars? The answer partly depends on whom you ask.

Bought a tablet factory – and built his own empire

In 1995, Thomas Eldered was CEO of one of Pharmacia’s factories in the Stockholm area when the Swedish pharmaceutical giant, after a takeover, decided to move its production abroad. 34-year-old Thomas was facing an imminent risk of losing his job. However, instead, it actually turned out to be the starting point for one of the biggest success stories in Swedish life science.

Biosimilarer ger prispress, men används de tillräckligt?

Biosimilarernas ankomst för drygt 16 år sedan väckte hopp om att många fler patienter skulle få tillgång till effektiva men annars mycket dyra behandlingar med biologiska läkemedel. Så hur bra har svensk sjukvård varit på att använda biosimilarerna? Svaret beror, åtminstone delvis, på vem man frågar.

Anders Blanck about his 17 years at Lif: “The industry is enjoying greater public trust now"

The announcement came as a surprise to those around him, but according to the protagonist himself, the timing was excellent. Anders Blanck is now leaving Lif – a decision that has been growing for some time. “I have been pretty much married to my mission. However, I will turn 56 this autumn, and if I’m going to do something else in my professional life, now is the time,” he says.

Här är XNK:s nya anläggning i Huddinge

Cellterapibolaget XNK Therapeutics meddelade på torsdagen att företagets nya GMP-anläggning med renrum nu står klar.

Innovationshubben i Matfors har haft sin första kund – "Full fart nu"

nu, och det är väldigt kul", säger Eva-Karin Gidlund, Head of Alliance and Innovation Management på Northx, till Life Science Sweden.

Oncorena rekryterar vd internt

Det blir en av grundarna till Oncorena som nu kliver in som vd för företaget.

Göran Stiernstedt: “We are the world’s worst at continuity”

Failed investments in primary care, an unreasonable system with online doctors and a public failure at coordinating the healthcare IT system. Göran Stiernstedt does not mind his language when describing the shortcomings of today’s healthcare system. “It makes me extremely frustrated,” he says.

A growing industry in Denmark: “One new life science company a week”

The life science sector in eastern Denmark continues to grow in the number of employees, as well as the number of companies. An emerging problem is the shortage of labour, a new report reveals.

IVI’s Director General on establishing in Sweden: Will need up to 40 employees

The International Vaccine Institute, IVI, hopes to have its first staff on-site in Stockholm within a couple of months, says the institute’s Director General Jerome Kim in an interview with Life Science Sweden.

Växande bransch i Danmark – "Ett nytt life science-företag i veckan"

Life science-sektorn i östra Danmark fortsätter att växa, både i antal anställda och antal företag. Ett uppseglande problem är bristen på arbetskraft, enligt en ny rapport.

Sobi och Sanofi får genombrottsstatus för behandling mot blödarsjuka

En behandling mot hemofili A, utvecklad av svenska Sobi tillsammans med Sanofi, har tilldelats genombrottsstatus i USA. Det är den första faktor VIII-behandling som ges sådan status.